Sage Therapeutics Stock News

The late-stage trial results for the company's major depressive disorder drug aren't impressing investors today.

The late-stage trial results for the company''s major depressive disorder drug aren''t impressing investors today.

Sage Therapeutics Inc (NASDAQ: SAGE ) and Biogen Inc (NASDAQ: BIIB ) said zuranolone combined with a standard of care antidepressant met the primary goal of showing rapid and significant reduction in depressive symptoms in a late-stage study . The drug, zuranolone, also met the study''s secondary goal of showing an improvement in symptoms … Full story available on Benzinga.com

Shares of Sage Therapeutics Inc. tumbled 11.2% in premarket trading on Wednesday after Wall Street raised questions about the durability of the experimental treatment for major depressive disorder that Sage is developing with Biogen Inc. . Biogen''s stock was up 0.7% in premarket trading. The companies had announced Monday morning that zuranolone met the primary endpoint in a Phase 3 clinical trial; however, some analysts still have concerns about the commercial appeal of the drug, if it is approved by the Food and Drug Administration. The data demonstrated that there was no statistical difference between giving zuranolone with an antidepressant and an antidepressant with placebo at the 42-day mark. "Some suggestion of near-term durability would be key to broaden commercial uptake of the agent (and perhaps ensure FDA comfort with the consistency of effects across the studies)," RBC Capital Markets analyst Brian Abrahams told investors on Monday. Sage''s stock is down 48.4% over the past year, while the broader S&P 500 is up 15.2%.

(Reuters) -Sage Therapeutics Inc said on Wednesday its drug along with an antidepressant helped improve depressive symptoms after three days in a late-stage study, paving way for the drug developer to submit data for U.S. approval this year.

Sage Therapeutics said Wednesday that its experimental anti-depression pill alleviated symptoms within three days of treatment, achieving the goal of a clinical trial involving patients with major depressive disorder.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced the CORAL Study in people with major depressive disorder (MDD) met the trial objectives, demonstrating a rapid and statistically significant reduction in depressive symptoms at Day 3 and over the 2-week treatment period, achieving the primary and key secondary endpoints. This significance was demonstrated at the first measured time point, Day 3, with zuranolone 50 mg co-init

Sage Therapeutics, Inc. (SAGE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sage Therapeutics, Inc. (SAGE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sage Therapeutics Inc. (NASDAQ:SAGE) price on Friday, February 11, fall -0.81% below its previous days close as a downside momentum from buyers pushed the stocks value to $43.04. A look at the stocks price movement, the close in the last trading session was $43.39, moving within a range at $42.56 and $44.50. The beta value Thinking Of Buying Sage Therapeutics Inc. (NASDAQ: SAGE) Stock? Heres What You Need To Know Read More »

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, February 24, 2022 at 8:00 a.m. ET to announce fourth quarter and full year 2021 financial results and discuss recent business updates. The webcast can be accessed on the investor page of Sage''s website at

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.